Close Menu

NEW YORK — Clear Labs said on Thursday that it has received Emergency Use Authorization from the US Food and Drug Administration for its Clear Dx SARS-CoV-2 novel descriptive diagnostic, the first nanopore sequencing-based test for SARS-CoV-2 to receive EUA.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.